Table 3.
Phase 2 Results: Participants’ Demographics and Clinical Characteristics
| Schizophrenia Patients (n = 31) | Negative Schizotypy (n = 27) | Positive Schizotypy (n = 18) | Healthy Controls (n = 29) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | F [3, 101]/χ2 | P | |
| Age (years) | 32.48 | 11.27 | 32.89 | 11.44 | 34.61 | 13.34 | 28.38 | 9.83 | 1.37 | .26 |
| Handedness (right vs left) | 28 vs 3 | 27 vs 0 | 18 vs 0 | 28 vs 1 | 4.71 | .20 | ||||
| Gender (male vs female) | 16 vs 15 | 11 vs 16 | 8 vs 10 | 11 vs 18 | 1.28 | .73 | ||||
| Education (years) | 12.55 | 3.21 | 12.15 | 2.97 | 11.89 | 3.77 | 14.86 | 2.23 | 5.44 | <.01 |
| Composition of unaffected relatives (parents vs siblings vs children) | 5 vs 20 vs 2 | 4 vs 13 vs 1 | 0.14 | .94 | ||||||
| Estimated IQ | 112.16 | 10.27 | 117.81 | 13.05 | 110.06 | 12.12 | 115.07 | 9.78 | 2.14 | .10 |
| Age of onset (years) | 29.27 | 10.56 | ||||||||
| Duration of untreated psychosis (months) | 22.79 | 40.57 | ||||||||
| Duration of illness (months) | 35.27 | 40.39 | ||||||||
| Chlorpromazine equivalence (mg/d) | 258.29 | 187.66 | ||||||||
| PANSS positive subscale | 8.16 | 2.79 | ||||||||
| PANSS negative subscale | 9.52 | 2.47 | ||||||||
| PANSS general subscale | 18.77 | 2.10 | ||||||||
| SANS affective flatting subscale | 0.67 | 0.61 | ||||||||
| SANS alogia subscale | 0.35 | 0.49 | ||||||||
| SANS avolition/ apathy subscale | 0.41 | 0.55 | ||||||||
| SANS anhedonia/ asociality subscale | 0.79 | 0.83 | ||||||||
| SANS attention subscale | 0.42 | 0.65 | ||||||||
Note: IQ, intelligence, PANSS, the Positive and Negative Syndrome Scale, SANS, the Scale for the Assessment of Negative Symptoms.
P < .05 are in bold.